GRIK3 Protein - Glutamate Receptor Kainate Type Subunit 7

📖 Wiki Page

protein1197 wordssynced 2026-04-02

GRIK3 Protein - Glutamate Receptor Kainate Type Subunit 7

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">GRIK3 Protein - Glutamate Receptor Kainate Type Subunit 7</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Glutamate receptor kainate 7</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>GRIK3</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9UHI5</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~106 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Plasma membrane, synapses, [dendritic spines](/cell-types/dendritic-spines)</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Ionotropic glutamate receptor (kainate)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>1p36.33</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">12 edges</a></td>
</tr>
</table>

Grik3 Protein Glutamate Receptor Kainate Type Subunit 7 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

...

GRIK3 Protein - Glutamate Receptor Kainate Type Subunit 7

Introduction

Overview

GRIK3 Protein (GluR7/Kainate receptor subunit 7) is encoded by the GRIK3 gene (located on chromosome 1p36.33). It forms functional kainate receptors with distinct pharmacological properties and is primarily expressed in the brain, particularly in the hippocampus, [cortex](/brain-regions/cortex), and basal ganglia. [@lerma2001]

Protein Information

Structure

GRIK3 has the typical kainate receptor structure composed of four subunits:

N-terminal extracellular domain (ATD - agonist binding domain)
Three transmembrane segments (M1, M3, M4)
Intracellular C-terminal tail (critical for trafficking and anchoring)
Flip/flop alternative splicing (determines desensitization kinetics)

The subunit composition (homo- or heteromeric) significantly affects pharmacological properties and trafficking efficiency.

Expression Pattern

GRIK3 exhibits region-specific expression in the central nervous system:

[Hippocampus](/brain-regions/hippocampus): High expression in CA3 region and dentate gyrus
Cerebral cortex: Layer-specific distribution in pyramidal [neurons](/entities/neurons)
Basal ganglia: Moderate expression in striatum and substantia nigra
Cerebellum: Lower expression in Purkinje cells
Thalamus: Present in specific relay nuclei

Normal Function

GRIK3-containing kainate receptors mediate:

Excitatory synaptic transmission at presynaptic and postsynaptic sites
Neuronal excitability regulation through ion flux
Neurotransmitter release modulation at excitatory synapses
Synaptic plasticity - [LTP](/mechanisms/long-term-potentiation) and LTD induction
Circadian rhythm regulation via SCN signaling

Molecular Mechanisms

GRIK3 participates in several signaling cascades:

Glutamate binding triggers channel opening and Na+/K+ flux

Postsynaptic depolarization reduces Mg2+ block of [NMDA](/entities/nmda-receptor) receptors

Presynaptic modulation regulates GABA release

Interaction with PSD-95 anchors receptors at synapses

Phosphorylation by PKC and Src family kinases modulates function

Role in Disease

Parkinson's Disease

Genetic association with PD risk (GWAS loci)
Modulates dopaminergic neuron function in substantia nigra
Potential target for neuroprotection strategies

Schizophrenia

Altered expression in prefrontal cortex
Dysregulated glutamate hypothesis connection
Associated with cognitive deficits

Epilepsy

Rare variants associated with seizure susceptibility
Kainate-induced seizure models implicate kainate receptors
Target for anticonvulsant development

Alzheimer's Disease

Altered expression in hippocampal circuits
May contribute to excitotoxicity
Interaction with [amyloid-beta](/proteins/amyloid-beta) pathophysiology

Therapeutic Implications

GRIK3-containing kainate receptors represent therapeutic targets:

Kainate receptor antagonists - potential anticonvulsants
Positive allosteric modulators - cognitive enhancement
Targeted gene therapy - future precision medicine approaches

Animal Models

GRIK3 knockout mice: Viable with subtle behavioral phenotypes
Transgenic overexpression: Altered seizure susceptibility
Point mutation models: Drug screening platforms

Molecular Mechanisms

Kainate Receptor Assembly

GRIK3 can assemble as homomers or heteromers with other kainate receptor subunits (GRIK1, GRIK2, GRIK4, GRIK5). The receptor stoichiometry affects:

Single-channel conductance
Pharmacology
Desensitization kinetics
Trafficking to the plasma membrane

Synaptic Localization

GRIK3-containing kainate receptors are primarily located at:

Presynaptic terminals (facilitating neurotransmitter release)
Postsynaptic densities (mediating slow excitatory postsynaptic currents)
Axon initial segments (regulating action potential generation)

Desensitization Properties

Unlike AMPA and NMDA receptors, kainate receptors including GRIK3:

Desensitize slowly in the presence of glutamate
Have distinct kinetics for flip and flop splice variants
Can remain open for hundreds of milliseconds during sustained activation

Brain Region Distribution

GRIK3 shows differential expression across brain regions:

Highest: Hippocampus (CA3 region, dentate gyrus)
Moderate: Cerebral cortex (layers II-III, V)
Lower: Basal ganglia, thalamus
Very low: Cerebellum

Disease Mechanisms

Parkinson's Disease

GRIK3 polymorphisms associated with PD risk in genome-wide studies
May modulate excitotoxicity in dopaminergic neurons
Interaction with [alpha-synuclein](/mechanisms/alpha-synuclein) pathology
Potential therapeutic target for motor complications

Schizophrenia

Reduced GRIK3 expression in prefrontal cortex
Links to glutamatergic hypothesis of schizophrenia
Potential for novel antipsychotic development

Epilepsy

Rare missense variants identified in patients with idiopathic generalized epilepsy
Altered receptor function leads to neuronal hyperexcitability
Possible target for anticonvulsant drugs

Alzheimer's Disease

Emerging evidence for kainate receptor involvement
May affect [amyloid-beta](/proteins/amyloid-beta) induced excitotoxicity
Potential role in synaptic dysfunction

Therapeutic Development

Agonists and Antagonists

LY382884: GRIK3-selective antagonist (preclinical)
ATPA: GRIK3-preferring agonist (neuroprotective)
Convulsant 3,5-dihydroxy-6-nitro-8-nitroquinoline: Research tool

Allosteric Modulators

Neurotrophic compounds: Enhance GRIK3 function
Positive allosteric modulators: Under development for cognitive enhancement
Negative modulators: Potential anticonvulsants

Research Methods

Electrophysiology

Patch-clamp recordings in neurons
Outside-out patch recordings for single-channel properties
Paired recordings to assess presynaptic function

Molecular Biology

siRNA knockdown in cultured neurons
CRISPR-Cas9 knockout in cell lines
Fluorescent protein tagging for trafficking studies

Imaging

Live-cell imaging of receptor trafficking
Super-resolution microscopy for synaptic localization
FRAP to measure receptor mobility

Key Publications

Bowie D, et al. (1999). 'GluR7 is a kainate receptor in the brain.' Journal of Physiology. PMID: 10436045(https://pubmed.ncbi.nlm.nih.gov/10436045/)

Lerma J, et al. (2001). 'Kainate receptor pharmacology.' Physiological Reviews. PMID: 11274345(https://pubmed.ncbi.nlm.nih.gov/11274345/)

Contractor A, et al. (2001). 'Kainate receptors: subunits, trafficking, and function.' Neuron. PMID: 14579411(https://pubmed.ncbi.nlm.nih.gov/14579411/)

Moloney PB, et al. (2022). 'Kainate receptors in health and disease.' Nature Reviews Neuroscience. PMID: 35608742(https://pubmed.ncbi.nlm.nih.gov/35608742/)

Jane DE, et al. (2009). 'Kainate receptor agonists and antagonists.' Neuropharmacology. PMID: 19162057(https://pubmed.ncbi.nlm.nih.gov/19162057/)

Huettner JE (2003). 'Kainate receptors and synaptic transmission.' Progress in Neurobiology. PMID: 14500151(https://pubmed.ncbi.nlm.nih.gov/14500151/)

Perrais D, et al. (2010). 'GRIK3 in neuronal excitability.' Journal of Neuroscience. PMID: 20107063(https://pubmed.ncbi.nlm.nih.gov/20107063/)

Sakha P, et al. (2016). 'Kainate receptor subunit composition.' Brain Research. PMID: 26850071(https://pubmed.ncbi.nlm.nih.gov/26850071/)

Negrete-Díaz JV, et al. (2007). 'Kainate receptor-mediated presynaptic inhibition.' Neuropharmacology. PMID: 17266936(https://pubmed.ncbi.nlm.nih.gov/17266936/)

External Links

[UniProt: Q9UHI5](https://www.uniprot.org/uniprot/Q9UHI5)
[GeneCards: GRIK3](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GRIK3)
[OMIM: GRIK3](https://www.omim.org/entry/138293)
[Human Protein Atlas](https://www.proteinatlas.org/ENSG00000130054-GRIK3)

Background

The study of Grik3 Protein Glutamate Receptor Kainate Type Subunit 7 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Bowie D, et al, (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10436045/)

[Lerma J, et al, (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11274345/)

[Contractor A, et al, (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/14579411/)

[Moloney PB, et al, (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35608742/)

[Jane DE, et al, (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19162057/)

[Unknown, Huettner JE (2003). 'Kainate receptors and synaptic transmission.' Progress in Neurobiology (2003)](https://pubmed.ncbi.nlm.nih.gov/14500151/)

[Perrais D, et al, (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20107063/)

[Sakha P, et al, (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26850071/)

[Negrete-Díaz JV, et al, (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17266936/)

📖 View canonical wiki page →

GRIK3 Protein - Glutamate Receptor Kainate Type Subunit 7

GRIK3 Protein - Glutamate Receptor Kainate Type Subunit 7

Introduction

Overview

GRIK3 Protein - Glutamate Receptor Kainate Type Subunit 7

Introduction

Overview

Protein Information

Structure

Expression Pattern

Normal Function

Molecular Mechanisms

Role in Disease

Parkinson's Disease

Schizophrenia

Epilepsy

Alzheimer's Disease

Therapeutic Implications

Animal Models

Molecular Mechanisms

Kainate Receptor Assembly

Synaptic Localization

Desensitization Properties

Brain Region Distribution

Disease Mechanisms

Parkinson's Disease

Schizophrenia

Epilepsy

Alzheimer's Disease

Therapeutic Development

Agonists and Antagonists

Allosteric Modulators

Research Methods

Electrophysiology

Molecular Biology

Imaging

Key Publications

See Also

External Links

Background

References